Cargando…
Altering cancer transcriptomes using epigenomic inhibitors
BACKGROUND: Due to the hyper-activation of WNT signaling in a variety of cancer types, there has been a strong drive to develop pathway-specific inhibitors with the eventual goal of providing a chemotherapeutic antagonist of WNT signaling to cancer patients. A new category of drugs, called epigeneti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506402/ https://www.ncbi.nlm.nih.gov/pubmed/26191083 http://dx.doi.org/10.1186/1756-8935-8-9 |